End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial
This study aimed to evaluate the usefulness of end-of-treatment (EOT)-PET for predicting PFS in FL patients in first relapse. EOT-PET examinations were performed between 6 and 8 weeks from the start of the last BR cycle. The primary endpoint was 1-year PFS. Key secondary endpoints were overall response rate (ORR), complete response rate (CRR), and 1-year overall survival (OS). Seventy-five patients were enrolled, and 8 were excluded from analysis. ORR was 86.6% and CRR was 59.7%. One-year PFS was 88.9% (95% confidence interval [CI] 80.7-94.3%) and 1-year OS in 75 patients was 97.3% (95% CI 89.6-99.3%). One-year PFS was significantly inferior in EOT-PET-positive patients (n = 9) compared with PET-negative patients (n = 58) (77.8% vs. 93.1%; p = 0.02). We confirmed that EOT-PET after second-line BR therapy could predict early progression in FL patients in first relapse.PMID:38519820 | DOI:10.1007/s12185-024-03738-8
Source: International Journal of Hematology - Category: Hematology Authors: Koji Kato Koji Izutsu Momoko Nishikori Hirohiko Shibayama Yoshinobu Maeda Kenichi Yoshimura Ukihide Tateishi Toshihiro Miyamoto Yasufumi Matsuda Jun Ishikawa Shinya Rai Tsutomu Takahashi Takahiro Yamauchi Itaru Matsumura Koichi Akashi Yuzuru Kanakura Junj Source Type: research